Alector, Inc.
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial forā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.36
Price+4.43%
$0.10
1Y
Price
Market Cap
$262.019m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1992.9%
EBITDA Margin-2192.2%
Net Profit Margin-4773.5%
Free Cash Flow Margin-1992.9%
EBITDA Margin-2192.2%
Net Profit Margin-4773.5%
Free Cash Flow MarginRevenue
$18.417m
-12.5%
1y CAGR-29.3%
3y CAGR-28.8%
5y CAGREarnings
-$125.388m
+12.3%
1y CAGR+0.3%
3y CAGR+0.8%
5y CAGREPS
-$1.19
+14.4%
1y CAGR+7.5%
3y CAGR+6.6%
5y CAGRBook Value
$10.382m
$239.916m
Assets$229.534m
Liabilities$34.548m
DebtDebt to Assets
14.4%
-0.3x
Debt to EBITDAFree Cash Flow
-$173.200m
+5.9%
1y CAGR+0.8%
3y CAGR-165.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company